LUX-Lung 6: A randomized, open-label, phase III study of afatinib (A) versus gemcitabine/cisplatin (GC) as first-line treatment for Asian patients (pts) with EGFR mutation-positive (EGFR M+) advanced adenocarcinoma of the lung.
Yi‐Long Wu(Guangdong Academy of Medical Sciences), Sarayut Lucien Geater(Prince of Songkla University), Dan Massey(Taipei Veterans General Hospital), Kye Young Lee(Konkuk University Medical Center), Chengping Hu(Central South University), Victoria Zazulina(Taipei Veterans General Hospital), Jiongjie Chen(Boehringer Ingelheim (China)), Wěi Li(Shougang (China)), Jian Hua Shi, Yunchao Huang(North China University of Water Resources and Electric Power), Mei Hou(Sichuan University), J. Feng(Hangzhou First People's Hospital), Shun Lü(Shanghai Jiao Tong University), Yang Shi(Harbin Medical University), Caicun Zhou(Tongji University)
Cited by 83
Related Papers
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
|New England Journal of Medicine|2009|8.2k
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
|New England Journal of Medicine|2016|3.3k